Formulation and Evaluation of Extended Release Matrix Tablets of Tenatoprazole Sodium using Synthetic Polymers

Abstract

Extended release formulations are designed to release their medication in a controlled manner at a predetermined rate, duration and location to achieve and maintain optimum therapeutic blood levels of a drug. The present investigation is aimed to formulate the extended release matrix tablets of Tenatoprazole sodium with various grades of different polymers like Carbopol, HPMC and Eudragit grades. The tablets were prepared by wet granulation technique. The prepared ER Matrix tablets were evaluated for various physico chemical parameters. All the formulations resulted in acceptable Pharmacopoeia limits. In-vitro drug release studies (USP dissolution rate test apparatus II, 75 rpm, 37°C ±0.5°C) using 0.1N hydrochloric acid (1.2 PH) for first 2 hrs and phosphate buffer (PH 6.8) as a dissolution medium (900ml) for the next 12 hrs. Among all the formulation F-5(drug: Carbopol-974P-NF in ratio of 1:1.5) shows better result upto 12 hours of the drug release was found to be 99.47±0.22 so it's an Optimized formulation.

Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives

“…In order to achieve a prolonged gastric acid suppression effect, attempts have been made to manufacture extended-release tablets of PPIs [ 268 , 269 , 270 , 271 , 272 ].…”

“…Divya et al [ 268 ] conducted an extensive study in which they tested different types of polymers and their concentrations for the preparation of tenatoprazole extended-release matrix tablets. The tablets were prepared by direct compression of a pre-granulated tablet mass containing polymers.…”

“…The polymers tested included Carbopol 941P and 974P-NF, as well as Eudragit L 100, S 100, RS 100 and RL 100 comprising from 16 to 32% of the tablet mass. Among the formulations produced, tablets containing 16% and 32% Carbopol 941P and 24% Carbopol 974P-NF had sufficient resistance to hydrochloric acid and released the drug substance for up to 12 h [ 268 ]. The same research group developed other extended-release tablets that contained ilaprazole as an active substance.…”